Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B


Alnylam Pharmaceuticals Inc's ALNY Q4 product revenues increased 76% Y/Y to $198.5 million, primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo.

  • Collaborations sales increased 18%, primarily due to increased revenue from collaboration agreements with Regeneron Pharmaceuticals Inc REGN and Novartis AG NVS.
  • Total sales increased to $258.5 million from $163.5 million, beating the consensus of $$233.62 million.
  • The Company posted an adjusted EPS loss of $(1.69), missing the consensus of $(1.54) compared to the $(1.60) a year ago.
  • Onpattro (patisiran) achieved sales of $139 million, +53.4% Y/Y, and attained over 2,050 patients worldwide on commercial Onpattro treatment as of December 31, 2021.
  • Givlaari (givosiran) clocked Q4 sales of $40.69 million, +83.7%. The Company attained over 350 patients worldwide on commercial Givlaari treatment.
  • Oxlumo (lumasiran) sales reached $19.2 million. Attained over 140 patients worldwide on commercial Oxlumo treatment.
  • Guidance: Alnylam expects FY22 product sales of $900 million – $1 billion, with collaborations & royalties sales of $175 million – $225 million.
  • Price Action: ALNY shares are up 2.13% at $154.62 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!